Breaking News Instant updates and real-time market news.

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24

On The Fly: After Hours Movers

HIGHER: KalVista (KALV), up 4.8% after Longwood Fund II reported an 8.7% stake in the company. LOWER: DBV Technologies (DBVT), down 53.3% after its PEPITES trial did not reach its primary endpoint.

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

KALV KalVista
$11.26

1.99 (21.47%)

10/16/17
BTIG
10/16/17
NO CHANGE
Target $27
BTIG
Buy
KalVista price target raised to $27 after Merck pact at BTIG
BTIG analyst Robert Hazlett said KalVista's (KALV) collaboration with Merck (MRK) underscores the material potential of the plasma kallikrein approach in diabetic macular edema. He also thinks that the larger company's agreement to take a stake signals confidence in KalVista's approach to hereditary angioedema treatment. He raised his price target KalVista to $27 from $18 following the collaboration agreement announcement and keeps a Buy rating on the shares, which are up 5% in pre-market trading.
08/31/17
BTIG
08/31/17
INITIATION
BTIG
Buy
KalVista initiated with a Buy at BTIG
BTIG analyst Robert Hazlett started coverage of KalVista with an $18 price target and a Buy rating. The analyst, noting that the company is developing "novel plasma kallikrein inhibitors for hereditary angioedema," or HAE, says that "plasma kallikrein is a validated therapeutic target in HAE." As a result, he thinks that even early data could eliminate the risk of the company's 8181 and 900 drugs, and he thinks that the program's peak revenue "could approach $800M.:" Target $18.
DBVT DBV Technologies
$48.07

0.92 (1.95%)

10/20/17
PIPR
10/20/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees ' increasingly favorable' risk/reward for Aimmune Phase III program
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan sees an "increasingly favorable" risk/reward for Aimmune Therapeutics' (AIMT) AR101 Phase III peanut allergy program heading into the clinical progress results in Q1 of 2018. Aimmune has a "best-in-class" approach to peanut allergy immunotherapy which can address at least 25%-40%) of the moderate to severe peanut allergic market, Duncan tells investors in a research note. The analyst believes some volatility in the shares is possible around the near-term Phase III Pepites results from "mind-share competitor" DBV Technologies (DBVT). Duncan views Aimmune as undervalued and keeps an Overweight rating on the shares with a $38 price target.
10/12/17
SBSH
10/12/17
NO CHANGE
Target $57
SBSH
Buy
DBV news today does not impact timelines for efficacy study, says Citi
Citi analyst Liav Abraham says she confirmed with management of DBV Technologies that today's announcement regarding the Realise study has no bearing on the timelines for readout of the pivotal efficacy study for Viaksin Peanut, the Pepites study, which remains on track for a headline data readout this month. The analyst remains "constructive" on the shares ahead of the Pepites data readout in October. She notes that Realise is DBV's second Phase III study for Viaskin Peanut, and is a safety study, unlike Pepites, which is an efficacy study. Abraham has a Buy rating on DBV with a $57 price target.
10/06/17
DBAB
10/06/17
NO CHANGE
Target $56
DBAB
Buy
DBV risk/reward favorable into Phase 3 readout, says Deutsche Bank
Deutsche Bank analyst Andrew Peters says the risk/reward for DBV Technologies, despite the stock rallying 31% year-to-date, is favorable into the Phase 3 data readout for Viaskin Peanut expected this month. The analyst continues to see a "strong rationale" for why the study should be successful. The current share value may still underappreciate the potential upside on positive data, Peters tells investors in a research note. He reiterates a Buy rating on DBV with a $56 price target.
10/02/17
JMPS
10/02/17
NO CHANGE
JMPS
Outperform
Parents excited about peanut allergy immunotherapy, says JMP Securities
After surveying over 60 parents with peanut allergic children, JMP Securities analyst Liisa Bayko said she was "surprised" that 85% of respondents indicated a willingness to adopt an immunotherapy to treat the allergy. While the survey group may represent a more engaged and proactive one than the larger population, Bayko said even 30% adoption would be significant as the peanut allergy market is "enormous". The analyst, who added the survey pointed to a place for both oral and epicutaneous approaches, keeps Outperform ratings on both DBV Technologies (DBVT) and Aimmune (AIMT).

TODAY'S FREE FLY STORIES

KBR

KBR

$19.19

0.3402 (1.80%)

, FLR

Fluor

$47.67

0.11 (0.23%)

09:55
11/22/17
11/22
09:55
11/22/17
09:55
Periodicals
KBR takeover potential speculation floated by blog »

Shares of KBR (KBR) are…

KBR

KBR

$19.19

0.3402 (1.80%)

FLR

Fluor

$47.67

0.11 (0.23%)

APO

Apollo Global

$30.27

0.1094 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SIG

Signet Jewelers

$54.48

1.69 (3.20%)

, FTR

Frontier Communications

$7.08

-0.15 (-2.07%)

09:55
11/22/17
11/22
09:55
11/22/17
09:55
Options
Early notable gainers among liquid option names on November 22nd »

Notable gainers among…

SIG

Signet Jewelers

$54.48

1.69 (3.20%)

FTR

Frontier Communications

$7.08

-0.15 (-2.07%)

BBBY

Bed Bath & Beyond

$20.27

-0.59 (-2.83%)

RRC

Range Resources

$17.56

0.38 (2.21%)

M

Macy's

$20.63

0.2113 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 20

    Dec

  • 18

    Mar

09:55
11/22/17
11/22
09:55
11/22/17
09:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

T

AT&T

$34.25

-0.08 (-0.23%)

, TWX

Time Warner

$89.74

0.18 (0.20%)

09:53
11/22/17
11/22
09:53
11/22/17
09:53
Conference/Events
FBN Securities strategist to hold an analyst/industry conference call »

FBN Securities…

T

AT&T

$34.25

-0.08 (-0.23%)

TWX

Time Warner

$89.74

0.18 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

CUB

Cubic

$62.00

1.25 (2.06%)

09:52
11/22/17
11/22
09:52
11/22/17
09:52
Technical Analysis
Technical View: Cubic up on mobile ticketing contract win for Rhein-Sieg area »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SAN

Banco Santander

$6.49

0.09 (1.41%)

09:50
11/22/17
11/22
09:50
11/22/17
09:50
Options
Santander Mar 7 calls active at the opening bell Wednesday »

Santander Mar 7 calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$2.31

-0.0094 (-0.41%)

09:46
11/22/17
11/22
09:46
11/22/17
09:46
Hot Stocks
22nd Century to discontinue U.S. sales of RED SUN brand cigarettes »

22nd Century Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
11/22/17
11/22
09:45
11/22/17
09:45
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

SAN

Banco Santander

, GME

GameStop

09:40
11/22/17
11/22
09:40
11/22/17
09:40
Options
Unusually active option classes on open November 22nd »

Unusual total active…

SAN

Banco Santander

GME

GameStop

HPE

HP Enterprise

HPQ

HP Inc.

CRM

Salesforce

SWKS

Skyworks

$110.25

0.46 (0.42%)

LRCX

Lam Research

$218.91

3.81 (1.77%)

SBUX

Starbucks

$57.26

0.45 (0.79%)

BIDU

Baidu

$244.30

5.76 (2.41%)

AMAT

Applied Materials

$58.80

1.18 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 25

    Jan

XLE

Energy Select Sector SPDR

09:40
11/22/17
11/22
09:40
11/22/17
09:40
Technical Analysis
Technical View: Energy Select Sector SPDR leads index on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

, HD

Home Depot

09:37
11/22/17
11/22
09:37
11/22/17
09:37
Recommendations
Lowe's, Home Depot analyst commentary  »

Lowe's price target…

LOW

Lowe's

HD

Home Depot

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

09:35
11/22/17
11/22
09:35
11/22/17
09:35
General news
U. Michigan sentiment preview: »

U. Michigan sentiment…

CHFS

CHF Solutions

$7.88

-0.24 (-2.96%)

09:31
11/22/17
11/22
09:31
11/22/17
09:31
Syndicate
CHF Solutions announces $18M public offering »

CHF Solutions announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTL

Mechel

09:31
11/22/17
11/22
09:31
11/22/17
09:31
Hot Stocks
Mechel announces reversal of Court decision »

Mechel reports a court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
11/22/17
11/22
09:30
11/22/17
09:30
General news
The U.S. durables report undershot estimates »

The U.S. durables report…

09:30
11/22/17
11/22
09:30
11/22/17
09:30
General news
Breaking General news story  »

Week of 11/19 Bloomberg…

SNPS

Synopsys

$89.38

0.48 (0.54%)

09:29
11/22/17
11/22
09:29
11/22/17
09:29
Recommendations
Synopsys analyst commentary  »

Synopsys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQUA

Evoqua Water

09:26
11/22/17
11/22
09:26
11/22/17
09:26
Hot Stocks
Evoqua Water names Dan Brailer head of investor relations »

Evoqua Water announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROK

Rockwell Automation

, EMR

Emerson

09:26
11/22/17
11/22
09:26
11/22/17
09:26
Recommendations
Rockwell Automation, Emerson analyst commentary  »

Latest Rockwell rebuff…

ROK

Rockwell Automation

EMR

Emerson

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/22/17
11/22
09:25
11/22/17
09:25
General news
Fed funds futures are slightly firmer toward the back end of the curve »

Fed funds futures are…

PBYI

Puma Biotechnology

$104.90

0.85 (0.82%)

09:24
11/22/17
11/22
09:24
11/22/17
09:24
Hot Stocks
Puma Biotechnology, Specialised Therapeutics Asia enter licensing agreement »

Puma Biotechnology and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

09:22
11/22/17
11/22
09:22
11/22/17
09:22
Hot Stocks
Whitman 'definitively' says not running for President or any other office »

Meg Whitman, speaking in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 11

    Dec

PG

Procter & Gamble

09:22
11/22/17
11/22
09:22
11/22/17
09:22
Hot Stocks
Trian comments on Procter & Gamble's contest to voting tabulation »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

, SFL

Ship Finance

09:22
11/22/17
11/22
09:22
11/22/17
09:22
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS: Deere…

DE

Deere

SFL

Ship Finance

EMR

Emerson

ROK

Rockwell Automation

FRO

Frontline

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 22

    Nov

  • 28

    Nov

SIG

Signet Jewelers

09:22
11/22/17
11/22
09:22
11/22/17
09:22
Recommendations
Signet Jewelers analyst commentary  »

Signet Jewelers price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.